Exploring gene editing as a potential therapeutic strategy for hemophilia

Area of Science:

• Genetics and Molecular Biology
• Hematology
• Biotechnology

Background:

• Hemophilia is an inherited bleeding disorder caused by mutations in F8 or F9 genes, leading to Factor VIII or IX deficiency.
• Current treatments like factor replacement and gene therapy have limitations including immunogenicity and transient expression.

Purpose of the Study:

• To review emerging gene editing technologies for hemophilia treatment.
• To discuss strategies for precise gene correction and stable transgene expression.

Main Methods:

• Utilizes programmable nucleases (CRISPR/Cas9, TALENs, ZFNs) to induce targeted DNA breaks.
• Explores gene editing strategies such as Homology Directed Repair (HDR) and Non-Homologous End Joining (NHEJ).
• Covers advanced techniques like base editing, prime editing, ex vivo editing in induced pluripotent stem cells (iPSCs), and LNP-based CRISPR delivery.

Main Results:

• Gene editing aims for precise mutation correction or targeted integration of coagulation factor cDNA for stable expression.
• Various tools and strategies are being developed to overcome limitations of current hemophilia therapies.
• Emerging delivery methods like LNP-based CRISPR show promise for efficient editing.

Conclusions:

• Gene editing presents a promising avenue for a permanent cure for hemophilia.
• Continued research into gene editing tools and delivery systems is crucial for clinical translation.
• This approach holds the potential to significantly improve long-term patient outcomes by addressing the root genetic cause.